Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients

M.L. Reale, R. Chiari, M. Tiseo, F. Vitiello, F. Barbieri, D. Cortinovis, G.L. Ceresoli, G. Finocchiaro, G.D. Romano, P.L. Piovano, A. Del Conte, G. Borra, F. Verderame, V. Scotti, D. Nonnis, D. Galetta, C. Sergi, M.R. Migliorino, G. Tonini, F. CecereR. Berardi, M.S. Pino, O. Martelli, A. Gelibter, A. Carta, E. Vattemi, M. Pagano, A. Zullo, S. Ferrari, A. Rossi, S. Novello

Research output: Contribution to journalArticlepeer-review


Objectives: Molecular diagnostics and care of non-small cell lung cancer (NSCLC) are continuously evolving. Few data document the current strategies to manage advanced NSCLC patients beyond progression in clinical practice. Patients and methods: Be-TeaM is an Italian multi-center observational study conducted on consecutive EGFR-mutated stage IV NSCLC patients, progressed during/after a first-line EGFR-TKI. It consists of a retrospective phase, from first-line EGFR-TKI therapy start until study entry (i.e. beginning of the diagnostic process), and a prospective phase, until treatment choice or for 3 months if no therapy was prescribed. Primary objective was to describe the diagnostic and therapeutic approaches adopted after progression in a real-world setting. Results: Of 308 patients enrolled in 63 centers from July 2017 to June 2018, 289 were included in the analysis. In first line, 53.3 % received gefitinib, 32.5 % afatinib and 14.2 % erlotinib. The testing rate (i.e. rate of all patients undergone any biopsy -liquid and/or tissue- for the T790 M detection) was 90.7 %, with liquid biopsy being the most frequently executed. Of 262 biopsied patients, 64.5 % underwent only 1 liquid biopsy, 10.7 % only 1 tissue biopsy and 18.3 % >1 biopsy, both liquid and solid in 85.4 %. The T790M positivity rate was 45.3 %; of 166 patients undergone only a liquid biopsy and tested for the mutation, 39.8 % were T790M+ and 60.2 % T790M-/undetermined. By the observation end, 87.9 % patients had a post-progression treatment chosen, osimertinib being the most frequent among the T790M+. Conclusion: Be-TeaM provides the first snapshot of current practices for the management of NSCLC patients beyond progression in Italy; in clinical practice, assessing the T790M status is not always feasible. © 2019
Original languageEnglish
Pages (from-to)71-79
Number of pages9
JournalLung Cancer
Publication statusPublished - 2020


  • Biopsy
  • Clinical practice
  • Italy
  • Second-line treatment
  • T790M
  • Testing rate
  • afatinib
  • epidermal growth factor receptor
  • erlotinib
  • gefitinib
  • osimertinib
  • adult
  • aged
  • Article
  • cancer chemotherapy
  • cancer diagnosis
  • cancer growth
  • cancer staging
  • cohort analysis
  • drug choice
  • EGFR gene
  • female
  • gene mutation
  • human
  • human tissue
  • liquid biopsy
  • major clinical study
  • male
  • middle aged
  • non small cell lung cancer
  • observational study
  • patient compliance
  • prescription
  • primary health care
  • priority journal
  • retrospective study
  • tumor biopsy


Dive into the research topics of 'Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients'. Together they form a unique fingerprint.

Cite this